KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Interest Expenses (2017 - 2026)

Aquestive Therapeutics has reported Interest Expenses over the past 9 years, most recently at $2.8 million for Q4 2025.

  • For Q4 2025, Interest Expenses changed 0.04% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $11.1 million, changed 0.02%, while the annual FY2025 figure was $11.1 million, 0.02% changed from the prior year.
  • Interest Expenses for Q4 2025 was $2.8 million at Aquestive Therapeutics, roughly flat from $2.8 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $2.8 million in Q3 2021 and troughed at $1.3 million in Q3 2023.
  • A 5-year average of $2.3 million and a median of $2.8 million in 2021 define the central range for Interest Expenses.
  • Biggest five-year swings in Interest Expenses: plummeted 41.4% in 2022 and later skyrocketed 121.34% in 2024.
  • Year by year, Interest Expenses stood at $1.7 million in 2021, then dropped by 5.39% to $1.6 million in 2022, then soared by 37.76% to $2.3 million in 2023, then rose by 22.26% to $2.8 million in 2024, then decreased by 0.04% to $2.8 million in 2025.
  • Business Quant data shows Interest Expenses for AQST at $2.8 million in Q4 2025, $2.8 million in Q3 2025, and $2.8 million in Q2 2025.